Effects of recombinant Clara cell secretory protein (rhCC10) on inflammatory-related matrix metalloproteinase activity in a preterm lamb model of neonatal respiratory distress

Pediatr Crit Care Med. 2007 Jan;8(1):40-6. doi: 10.1097/01.PCC.0000253022.10607.61.

Abstract

Objective: To test the hypothesis that recombinant Clara cell secretory protein (rhCC10) instillation would foster improved lung function, acute structural preservation, and attenuation of matrix metalloproteinase (MMP) activity in a surfactant-deficient, mechanically ventilated lung.

Design: Interventional laboratory study.

Setting: An academic medical research facility in the northeastern United States.

Subjects: Sedated, ventilated premature lambs.

Interventions: Preterm lambs (n = 18; 126 +/- 3 days gestation) were instrumented, ventilated, and treated with 100 mg/kg exogenous surfactant. Lambs were randomized to receive 0, 0.5, or 5.0 mg/kg rhCC10 (n = 6 per group) and were ventilated for 4 hrs.

Measurements and main results: Posttreatment, lung function and cardiopulmonary stability were monitored for the ventilation period and then animals were killed for in vitro surfactant function analysis, lung histomorphometry, and analysis of MMP-2, -7, and -9 as well as their tissue inhibitors (TIMP)-1 and -2. Ventilation efficiency and pulmonary compliance were improved in the 5.0-mg/kg rhCC10 group by 4 hrs. Lung expansion was variable in the apical regions only. MMP-2 quantity was greater in the apical than the base lung regions of rhCC10-treated groups, and rhCC10 decreased MMP-7 in the base of the lung.

Conclusions: These data suggest that improved lung function in the surfactant-treated preterm lamb following intratracheal rhCC10 may be related to the reduction of proteolytic activity of MMP-7.

Publication types

  • Comparative Study
  • Research Support, N.I.H., Extramural

MeSH terms

  • Animals
  • Animals, Newborn
  • Disease Models, Animal
  • Enzyme Inhibitors / administration & dosage
  • Enzyme Inhibitors / therapeutic use*
  • Humans
  • Infant, Newborn
  • Lung / pathology
  • Lung Compliance
  • Metalloproteases / antagonists & inhibitors
  • Metalloproteases / metabolism*
  • Protease Inhibitors / analysis
  • Pulmonary Alveoli / pathology
  • Pulmonary Surfactants / therapeutic use
  • Respiration, Artificial*
  • Respiratory Distress Syndrome, Newborn / drug therapy
  • Respiratory Distress Syndrome, Newborn / enzymology
  • Respiratory Distress Syndrome, Newborn / pathology
  • Respiratory Distress Syndrome, Newborn / therapy*
  • Sheep
  • Time Factors
  • Tissue Inhibitor of Metalloproteinase-1 / analysis
  • Tissue Inhibitor of Metalloproteinase-2 / analysis
  • Treatment Outcome
  • Uteroglobin / administration & dosage
  • Uteroglobin / therapeutic use*

Substances

  • Enzyme Inhibitors
  • Protease Inhibitors
  • Pulmonary Surfactants
  • SCGB1A1 protein, human
  • Tissue Inhibitor of Metalloproteinase-1
  • Tissue Inhibitor of Metalloproteinase-2
  • Uteroglobin
  • Metalloproteases